| scholarly article | Q13442814 |
| P50 | author | Nicolas Venisse | Q40834352 |
| P2093 | author name string | Antoine Dupuis | |
| Michel Pinsard | |||
| Anne Veinstein | |||
| René Robert | |||
| Julie Badin | |||
| P2860 | cites work | A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study | Q29615430 |
| Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data | Q31122362 | ||
| Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? | Q33545113 | ||
| Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms | Q33694513 | ||
| Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. | Q33759273 | ||
| Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis | Q33826400 | ||
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 | ||
| Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity | Q33977062 | ||
| Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury | Q34108507 | ||
| Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. | Q34108527 | ||
| A suggested approach to once‐daily aminoglycoside dosing | Q34347273 | ||
| Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. | Q34480866 | ||
| Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality | Q35139187 | ||
| Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing | Q36666776 | ||
| Diagnosing model diagnostics | Q36850144 | ||
| Back to the future: using aminoglycosides again and how to dose them optimally | Q36916092 | ||
| Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens | Q37214124 | ||
| Pharmacokinetic issues for antibiotics in the critically ill patient | Q37399820 | ||
| Some current issues in the pharmacokinetics/pharmacodynamics of antimicrobials in intensive care | Q37770953 | ||
| Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis | Q37773767 | ||
| Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis | Q37781944 | ||
| Aminoglycoside use in renal failure | Q37808935 | ||
| Optimizing aminoglycoside use. | Q37818801 | ||
| Evaluation of four once-daily aminoglycoside dosing nomograms | Q39221496 | ||
| Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration | Q40284216 | ||
| Once-daily dosing of aminoglycosides: review and recommendations for clinical practice | Q41530531 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Management of Aminoglycosides in the Intensive Care Unit | Q42908869 | ||
| Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients | Q43738821 | ||
| Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? | Q43872720 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. | Q51639404 | ||
| Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. | Q51723077 | ||
| Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. | Q51930719 | ||
| Gentamicin volume of distribution in critically ill septic patients | Q57238214 | ||
| Variability in aminoglycoside pharmacokinetics in critically ill surgical patients | Q68287019 | ||
| Aminoglycoside volume of distribution and illness severity in critically ill septic patients | Q70776962 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal dialysis | Q202301 |
| gentamicin | Q422482 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 977-982 | |
| P577 | publication date | 2012-12-10 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered | |
| P478 | volume | 57 |
| Q38261172 | Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much". |
| Q38693212 | Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View |
| Q38843412 | Optimization of anti-infective dosing regimens during online haemodiafiltration |
| Q35819409 | Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction |
| Q39071799 | Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy. |
| Q38263150 | Significant publications on infectious diseases pharmacotherapy in 2013. |
| Q54675401 | We Give Aminoglycoside Antibiotics at the End of Hemodialysis. |
Search more.